Proprio

Proprio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $66M

Overview

Proprio is a private medical technology company pioneering an AI-driven surgical intelligence platform. Its flagship product, Paradigm™, is an FDA-cleared navigation system that uses light-field imaging and computer vision to provide continuous, radiation-free 3D visualization and measurements during surgery, starting with spinal applications. The platform aims to enhance surgical precision, reduce procedure time and radiation exposure, and generate standardized intraoperative data to power system-wide learning and optimization. Proprio's vision extends beyond navigation to building a global surgical data network that compounds insights across procedures and institutions.

Spine SurgeryNeurosurgery

Technology Platform

Paradigm™: An AI-driven surgical intelligence platform using light-field imaging, computer vision, and proprietary algorithms for continuous, radiation-free 3D anatomical modeling and real-time measurement during surgery. It generates structured intraoperative data to power a learning system.

Funding History

2
Total raised:$66M
Series B$43M
Series A$23M

Opportunities

The primary opportunity is to disrupt the multi-billion dollar surgical navigation market by offering a superior, data-generating platform that improves outcomes and OR efficiency.
The larger, long-term opportunity lies in creating and monetizing a proprietary global dataset of structured surgical data, enabling applications in training, quality improvement, and advanced AI surgical assistance.

Risk Factors

Key risks include challenging commercialization against entrenched competitors, the need for robust long-term clinical validation, proving a clear ROI to cost-conscious hospitals, and navigating the complex regulatory landscape for AI and patient data as the company builds its surgical data network.

Competitive Landscape

Proprio competes in the surgical navigation market dominated by large medtech companies like Medtronic (StealthStation), Stryker (SpineMask, Q Guidance), and Zimmer Biomet (Rosa). Its differentiation is its continuous, radiation-free segmental tracking and its foundational AI model designed to learn from data, positioning it as a next-generation intelligence platform rather than just a navigation tool.